Evaluating baricitinib for treating juvenile idiopathic arthritis in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and effectiveness of baricitinib in children aged 1 to less than 18 years who have juvenile idiopathic arthritis (JIA). Participants must have previously completed a study involving baricitinib and cannot have had a permanent discontinuation of the drug. The study aims to build on prior findings to determine if continued treatment is beneficial for this age group. The focus is on various forms of JIA, including polyarticular and systemic types.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion Criteria:

* Participants must not have had a permanent discontinuation of baricitinib in the prior study.
* Participants must have not developed an allergy to baricitinib.

Where it's running

• UZ Gent
  Ghent, Belgium Recruiting
• UZ Leuven
  Leuven, Belgium Recruiting
• Faculdade de Medicina da UNESP
  Botucatu, Brazil Recruiting
• Universidade Federal de Sao Paulo
  São Paulo, Brazil Recruiting
• Instituto da Crianca do Hospital das Clinicas da FMUSP
  São Paulo, Brazil Recruiting
• Detska nemocnice FN Brno
  Brno, Czechia Recruiting

+27 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using infrared cameras to help detect juvenile arthritis in kids

  This study tests whether infrared thermography can help identify joint inflammation in children with juvenile idiopathic arthritis compared with standard tests.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07914179

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Oral health, saliva bacteria, and disease activity in children with JIA

  This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Pudongxinqu · NCT07799831

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

• Olokizumab treatment for children with polyarticular juvenile idiopathic arthritis

  This test gives weight-based doses of olokizumab every 4 weeks to see if it helps control polyarticular juvenile idiopathic arthritis and is safe for children aged 2–17.

  Recruiting at 14 sites Phase 2 R-Pharm · Kazan' and 13 other locations · NCT07517575

• Telitacicept plus baricitinib for refractory rheumatoid arthritis

  This test tries combining telitacicept with baricitinib to see if it helps adults with refractory rheumatoid arthritis who haven't improved on other treatments.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07491016

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.